Gilead Sciences Inc (GILD)

78.97
0.28 0.35
NASDAQ : Health Care
Prev Close 79.25
Open 79.12
Day Low/High 78.51 / 79.50
52 Wk Low/High 77.92 / 120.37
Volume 6.84M
Avg Volume 10.60M
Exchange NASDAQ
Shares Outstanding 1.32B
Market Cap 106.39B
EPS 12.40
P/E Ratio 7.11
Div & Yield 1.88 (2.30%)

Latest News

Jim Cramer -- Gilead Needs to Make an Acquisition

Jim Cramer -- Gilead Needs to Make an Acquisition

Investors shouldn't give up on Gilead's Hep. C drug, Cramer says.

Gilead (GILD) Stock Falls on Ratings Downgrade

Gilead (GILD) Stock Falls on Ratings Downgrade

Gilead (GILD) stock was down in pre-market trading on Tuesday after Leerink cut its rating on shares to 'market perform.'

Analysts' Actions -- AutoZone, Eli Lilly, J.M. Smucker, Toll Brothers and More

Analysts' Actions -- AutoZone, Eli Lilly, J.M. Smucker, Toll Brothers and More

Here are Tuesday's top research calls, including upgrades for AutoZone and Eli Lilly, and downgrades for J.M. Smucker and Toll Brothers.

Wall Street Sells Off on Worries Over Clinton-Trump Showdown

Wall Street Sells Off on Worries Over Clinton-Trump Showdown

Stocks end Monday's session sharply lower as Wall Street grows restless ahead of the first presidential debate.

Biotech ETFs May Be a Prescription for Investment Success, Especially if Trump Becomes President

Biotech ETFs May Be a Prescription for Investment Success, Especially if Trump Becomes President

Driving sector performance are a recent series of mergers and acquisitions, including Horizon Pharma's purchase of Raptor Pharmaceutical Corp. Then there's the political boost...

Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies

Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies

Stocks hold near session lows by mid-afternoon Monday as Wall Street grows restless ahead of the first presidential debate.

Will Gilead (GILD) Stock Be Helped by Positive Crohn's Drug Results?

Will Gilead (GILD) Stock Be Helped by Positive Crohn's Drug Results?

Leerink said on Monday that Gilead (GILD) could see a 'slight uplift' in its research and development strategy on partner Galapagos' (GLPG) positive drug trial results.

Stocks Fall as Health Care Slumps Ahead of Presidential Debate

Stocks Fall as Health Care Slumps Ahead of Presidential Debate

Stocks are lower Monday as Wall Street's attention shifts to the looming presidential debate from central bank policy.

Sentiments About the Market, Oil, Retailers: Jim Cramer's Views

Sentiments About the Market, Oil, Retailers: Jim Cramer's Views

Jim Cramer shares his views on why the market is hated and oil charades from the producing nations.

Gilead (GILD) Stock Higher, Citigroup: Hepatitis C Drug Sales Improving

Gilead (GILD) Stock Higher, Citigroup: Hepatitis C Drug Sales Improving

Citigroup analysts say recent IMS Health data show that Gilead (GILD) Hepatitis C drug sales have grown quarter-over-quarter.

Cramer: Here Are the Reasons the Market Is Hated

Cramer: Here Are the Reasons the Market Is Hated

Apart from the Fed, there are other factors that make investors nervous.

Gilead Sciences (GILD) Stock Lower Despite Bullish Gabelli Note

Gilead Sciences (GILD) Stock Lower Despite Bullish Gabelli Note

Gilead Sciences' (GILD) NASH liver disease pipeline is "very attractive," Gabelli said in an analyst note on Thursday.

Allergan's Boldness may not be Limited to Tobira Deal

Allergan's Boldness may not be Limited to Tobira Deal

The Irish drugmaker isn't likely done making deals, even though it just made two, and it could take a look at Alder Biopharmaceuticals next, analysts believe.

Gilead Terminates Phase 2/3 Study Of GS-5745 In Patients With Ulcerative Colitis

Gilead Terminates Phase 2/3 Study Of GS-5745 In Patients With Ulcerative Colitis

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company is stopping its combined Phase 2/3 clinical study of GS-5745, an investigational anti-MMP9 antibody, among patients with moderately to severely active...

Gilead Sciences (GILD) Stock Lower, Gabelli: Allergan Could Be Buyer

Gilead Sciences (GILD) Stock Lower, Gabelli: Allergan Could Be Buyer

Gabelli analysts say Gilead Sciences (GILD) could be the next possible takeover target by Allergan (AGN), as the company has a 'deep pipeline' of NASH drugs.

Here's a Reason Why Gilead (GILD) Stock Is Gaining Today

Here's a Reason Why Gilead (GILD) Stock Is Gaining Today

Gilead (GILD) stock was climbing Tuesday afternoon after Allergan (AGN) said it would buy Tobira (TBRA).

Gilead Is in Breakout Mode

Gilead Is in Breakout Mode

Shares of Gilead Sciences are surging today. Here's how to trade the stock from here.

Know When and How Buybacks Are Worth Buying

Know When and How Buybacks Are Worth Buying

Buybacks may alert investors to a great opportunity or worthless paperwork.

You've Got the Brains, I've Got the Book, Let's Make Lots of Money

You've Got the Brains, I've Got the Book, Let's Make Lots of Money

Emulate Graham and Buffett with Greenblatt’s 'Magic Formula' screen.

Gilead: Horse of a Different, uh, Color

Gilead: Horse of a Different, uh, Color

The once-mighty biotech has fallen, but entry opportunities will surface.

Gilead (GILD) Stock Down, Jefferies: $5 Billion Debt Offering Suggests 'Imminent' Deal

Gilead (GILD) Stock Down, Jefferies: $5 Billion Debt Offering Suggests 'Imminent' Deal

Jefferies analysts say Gilead's (GILD) $5 billion debt offering could suggest that the company plans to seek out one or several acquisitions, possibly in the orphan diseases sector.

Gilead Prices $5 Billion Of Senior Unsecured Notes

Gilead Prices $5 Billion Of Senior Unsecured Notes

Gilead Sciences, Inc. (NASDAQ:GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $5 billion, in an underwritten, registered public offering, consisting of five tranches: ...

Gilead's Pipeline, Maligned by Investors, Still Packed With 4Q Clinical Trial Readouts

Gilead's Pipeline, Maligned by Investors, Still Packed With 4Q Clinical Trial Readouts

Collectively, the data will give investors a clearer measure of Gilead's internal drug development efforts outside of its core hepatitis C and HIV strengths.

Will Gilead Sciences (GILD) Stock Be Affected by Lower Price Target?

Will Gilead Sciences (GILD) Stock Be Affected by Lower Price Target?

Credit Suisse trimmed its price target on shares of Gilead Sciences (GILD) to $95 in a note on Wednesday.

Buy Gilead and Wait for the Rebound

Buy Gilead and Wait for the Rebound

Gilead is a cheap stock with solid turnaround potential and a healthy dividend.

Gilead Sciences (GILD) Stock Up, CEO Milligan Talks M&A Strategy

Gilead Sciences (GILD) Stock Up, CEO Milligan Talks M&A Strategy

Gilead Sciences (GILD) CEO John Milligan said on Monday that the company won't rule out a large deal but would prefer a series of smaller ones.

3 Stocks That Could Still Rally

It's been a nasty decline, but if we rally, these three have best charts.

5 Questions and Answers Take a Measure of Biotech Investor Sentiment

5 Questions and Answers Take a Measure of Biotech Investor Sentiment

How will biotech stocks end the year? Will FDA approve Sarepta's drug? Will Gilead finally buy another company?